1. Home
  2. CAG vs TGTX Comparison

CAG vs TGTX Comparison

Compare CAG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConAgra Brands Inc.

CAG

ConAgra Brands Inc.

N/A

Current Price

$13.15

Market Cap

7.1B

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$53.87

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAG
TGTX
Founded
1919
1993
Country
United States
United States
Employees
26100
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
8.5B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
CAG
TGTX
Price
$13.15
$53.87
Analyst Decision
Hold
Buy
Analyst Count
17
8
Target Price
$14.38
★ $69.71
AVG Volume (30 Days)
★ 8.2M
1.4M
Earning Date
09-30-2026
11-02-2026
Dividend Yield
★ 5.21%
N/A
EPS Growth
N/A
★ 1746.67
EPS
★ 0.36
0.17
Revenue
★ $1,500,000,000.00
$2,785,000.00
Revenue This Year
N/A
$55.80
Revenue Next Year
$0.20
$37.28
P/E Ratio
★ N/A
$328.53
Revenue Growth
★ N/A
N/A
52 Week Low
$12.53
$26.76
52 Week High
$20.32
$59.30

Technical Indicators

Market Signals
Indicator
CAG
TGTX
Relative Strength Index (RSI) 21.33 52.86
Support Level $12.67 $51.76
Resistance Level $14.55 $58.26
Average True Range (ATR) 0.38 2.13
MACD -0.18 -0.16
Stochastic Oscillator 4.69 56.39

Price Performance

Historical Comparison
CAG
TGTX

About CAG ConAgra Brands Inc.

Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: